Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XW015
- Development stage
- Unknown
- Lead developer
- Sciwind Biosciences
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
XW015 is a long-acting, peptide-based amylin receptor agonist being developed by Hangzhou Sciwind Biosciences for the treatment of obesity and type 2 diabetes. As an amylin analog, it mimics the effects of the endogenous hormone amylin, which is co-secreted with insulin to regulate postprandial glucose levels, enhance satiety, and reduce appetite. Through peptide engineering, Sciwind has addressed the stability challenges typically associated with amylin at neutral pH, potentially allowing XW015 to be co-formulated with GLP-1 receptor agonists. The drug is administered via subcutaneous injection and is being developed globally in partnership with Verdiva Bio for markets outside of Greater China and South Korea.
- Other names
- Amylin Injection
Beyond the preview
Go deeper on XW015.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XW015.